Cargando…

A Long-Acting Thermoresponsive Injectable Formulation of Tin Protoporphyrin Sustains Antitubercular Efficacy in a Murine Infection Model

[Image: see text] Tuberculosis is the leading cause of death from a single infectious agent, ranking above the human immunodeficiency virus (HIV). Effective treatment using antibiotics is achievable, but poor patient compliance constitutes a major challenge impeding successful pharmacotherapeutic ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Adeleke, Oluwatoyin A., Fisher, Logan, Moore, Ian N., Nardone, Glenn A., Sher, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887855/
https://www.ncbi.nlm.nih.gov/pubmed/33615179
http://dx.doi.org/10.1021/acsptsci.0c00185
_version_ 1783652055594827776
author Adeleke, Oluwatoyin A.
Fisher, Logan
Moore, Ian N.
Nardone, Glenn A.
Sher, Alan
author_facet Adeleke, Oluwatoyin A.
Fisher, Logan
Moore, Ian N.
Nardone, Glenn A.
Sher, Alan
author_sort Adeleke, Oluwatoyin A.
collection PubMed
description [Image: see text] Tuberculosis is the leading cause of death from a single infectious agent, ranking above the human immunodeficiency virus (HIV). Effective treatment using antibiotics is achievable, but poor patient compliance constitutes a major challenge impeding successful pharmacotherapeutic outcomes. This is often due to the prolonged treatment periods required and contributes significantly to the rising incidence of drug resistance, which is a major cause of tuberculosis mortality. Thus, innovative interventions capable of encouraging compliance and decreasing lengthy and frequent dosing are needed. Previously, aqueous tin protoporphyrin IX (SnPPIX), a heme oxygenase-1 inhibitor, administered as multiple daily intraperitoneal (IP) injections, showed considerable antitubercular efficacy and treatment shortening capabilities as a host-directed therapy in infected mice. Since daily IP injection is a clinically impractical administration approach, this proof-of-concept study aims to develop a novel, sustained action injectable formulation of SnPPIX for safe intramuscular (IM) administration. Herein, a SnPPIX-loaded poloxamer-poly(acrylic acid)-based thermoresponsive injectable formulation (SnPPIX-TIF) is designed for effective IM delivery. Results show SnPPIX-TIF is microparticulate, syringeable, injectable, and exhibits complete in vitro/in vivo gelation. Administered once weekly, SnPPIX-TIF significantly prolonged absorption and antimicrobial efficacy in infected mice. In addition, SnPPIX-TIF is well-tolerated in vivo; results from treated animals show no significant histopathologic alterations and were indistinguishable from the untreated control group, thus supporting its biocompatibility and preclinical safety. Overall, the IM delivery of the thermoresponsive injectable formulation safely sustains antitubercular effect in an infected murine model and decreases the number of injections required, signifying a potentially practical approach for future clinical translation.
format Online
Article
Text
id pubmed-7887855
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-78878552021-06-22 A Long-Acting Thermoresponsive Injectable Formulation of Tin Protoporphyrin Sustains Antitubercular Efficacy in a Murine Infection Model Adeleke, Oluwatoyin A. Fisher, Logan Moore, Ian N. Nardone, Glenn A. Sher, Alan ACS Pharmacol Transl Sci [Image: see text] Tuberculosis is the leading cause of death from a single infectious agent, ranking above the human immunodeficiency virus (HIV). Effective treatment using antibiotics is achievable, but poor patient compliance constitutes a major challenge impeding successful pharmacotherapeutic outcomes. This is often due to the prolonged treatment periods required and contributes significantly to the rising incidence of drug resistance, which is a major cause of tuberculosis mortality. Thus, innovative interventions capable of encouraging compliance and decreasing lengthy and frequent dosing are needed. Previously, aqueous tin protoporphyrin IX (SnPPIX), a heme oxygenase-1 inhibitor, administered as multiple daily intraperitoneal (IP) injections, showed considerable antitubercular efficacy and treatment shortening capabilities as a host-directed therapy in infected mice. Since daily IP injection is a clinically impractical administration approach, this proof-of-concept study aims to develop a novel, sustained action injectable formulation of SnPPIX for safe intramuscular (IM) administration. Herein, a SnPPIX-loaded poloxamer-poly(acrylic acid)-based thermoresponsive injectable formulation (SnPPIX-TIF) is designed for effective IM delivery. Results show SnPPIX-TIF is microparticulate, syringeable, injectable, and exhibits complete in vitro/in vivo gelation. Administered once weekly, SnPPIX-TIF significantly prolonged absorption and antimicrobial efficacy in infected mice. In addition, SnPPIX-TIF is well-tolerated in vivo; results from treated animals show no significant histopathologic alterations and were indistinguishable from the untreated control group, thus supporting its biocompatibility and preclinical safety. Overall, the IM delivery of the thermoresponsive injectable formulation safely sustains antitubercular effect in an infected murine model and decreases the number of injections required, signifying a potentially practical approach for future clinical translation. American Chemical Society 2020-12-18 /pmc/articles/PMC7887855/ /pubmed/33615179 http://dx.doi.org/10.1021/acsptsci.0c00185 Text en This article not subject to U.S. Copyright. Published 2020 by American Chemical Society This is an open access article published under a Creative Commons Non-Commercial No Derivative Works (CC-BY-NC-ND) Attribution License (http://pubs.acs.org/page/policy/authorchoice_ccbyncnd_termsofuse.html) , which permits copying and redistribution of the article, and creation of adaptations, all for non-commercial purposes.
spellingShingle Adeleke, Oluwatoyin A.
Fisher, Logan
Moore, Ian N.
Nardone, Glenn A.
Sher, Alan
A Long-Acting Thermoresponsive Injectable Formulation of Tin Protoporphyrin Sustains Antitubercular Efficacy in a Murine Infection Model
title A Long-Acting Thermoresponsive Injectable Formulation of Tin Protoporphyrin Sustains Antitubercular Efficacy in a Murine Infection Model
title_full A Long-Acting Thermoresponsive Injectable Formulation of Tin Protoporphyrin Sustains Antitubercular Efficacy in a Murine Infection Model
title_fullStr A Long-Acting Thermoresponsive Injectable Formulation of Tin Protoporphyrin Sustains Antitubercular Efficacy in a Murine Infection Model
title_full_unstemmed A Long-Acting Thermoresponsive Injectable Formulation of Tin Protoporphyrin Sustains Antitubercular Efficacy in a Murine Infection Model
title_short A Long-Acting Thermoresponsive Injectable Formulation of Tin Protoporphyrin Sustains Antitubercular Efficacy in a Murine Infection Model
title_sort long-acting thermoresponsive injectable formulation of tin protoporphyrin sustains antitubercular efficacy in a murine infection model
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887855/
https://www.ncbi.nlm.nih.gov/pubmed/33615179
http://dx.doi.org/10.1021/acsptsci.0c00185
work_keys_str_mv AT adelekeoluwatoyina alongactingthermoresponsiveinjectableformulationoftinprotoporphyrinsustainsantitubercularefficacyinamurineinfectionmodel
AT fisherlogan alongactingthermoresponsiveinjectableformulationoftinprotoporphyrinsustainsantitubercularefficacyinamurineinfectionmodel
AT mooreiann alongactingthermoresponsiveinjectableformulationoftinprotoporphyrinsustainsantitubercularefficacyinamurineinfectionmodel
AT nardoneglenna alongactingthermoresponsiveinjectableformulationoftinprotoporphyrinsustainsantitubercularefficacyinamurineinfectionmodel
AT sheralan alongactingthermoresponsiveinjectableformulationoftinprotoporphyrinsustainsantitubercularefficacyinamurineinfectionmodel
AT adelekeoluwatoyina longactingthermoresponsiveinjectableformulationoftinprotoporphyrinsustainsantitubercularefficacyinamurineinfectionmodel
AT fisherlogan longactingthermoresponsiveinjectableformulationoftinprotoporphyrinsustainsantitubercularefficacyinamurineinfectionmodel
AT mooreiann longactingthermoresponsiveinjectableformulationoftinprotoporphyrinsustainsantitubercularefficacyinamurineinfectionmodel
AT nardoneglenna longactingthermoresponsiveinjectableformulationoftinprotoporphyrinsustainsantitubercularefficacyinamurineinfectionmodel
AT sheralan longactingthermoresponsiveinjectableformulationoftinprotoporphyrinsustainsantitubercularefficacyinamurineinfectionmodel